Advertisement

The GM1 Gangliosidoses

  • Gustavo Charria-Ortiz

The gangliosidoses are a group of lysosomal storage diseases characterized by the accumulation of these complex glycolipids in multiple organs of the body. They manifest a predominantly neurological phenotype, a fact that is probably related to their high prevalence in nervous tissues. The typical presentation is that of a progressive neurodegenerative disease with onset in early life followed by loss of acquired developmental milestones, dementia, and worsening neurological deficits. Early death is common, except perhaps in late-onset variants. Systemic manifestations in the form of visceromegaly or skeletal deformities are preferentially seen in the aggressive variants of GM1 gangliosidosis (i.e., infantile), whereas they are typically absent in GM2 gangliosidosis (except for Sandhoff’s disease, which may present with mild visceromegaly). Depending upon the severity of the enzymatic defect, they show different rates of clinical progression and involvement, with severe deficiencies leading to the most aggressive forms in an infantile and acute or subacute fashion, whereas milder ones have an onset later in life and slower clinical progression.

Keywords

Sialic Acid Keratan Sulfate Lysosomal Storage Disease Oligosaccharide Chain Spastic Quadriplegia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achord D, Brot F, Gonzalez-Noriega A, Sly W, Stahl P (1977) Human beta-glucuro-nidase. II. Fate of infused human placental beta-glucuronidase in the rat. Pediatr Res. 11:816.CrossRefPubMedGoogle Scholar
  2. Al-Essa MA, Bakheet SM, Patay ZJ, Nounou RM, Ozand PT (1999) Cerebral fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI, and clinical observations in a patient with infantile G(M1) gangliosidosis. Brain Dev. 2:559-562.CrossRefGoogle Scholar
  3. Alroy J, Orgad U, Ucci AA, Schelling SH, Schunk KL, Warren CD, Raghavan SS, Kolodny EH (1985) Neurovisceral and skeletal GM1-gangliosidosis in dogs with beta-galactosidase deficiency. Science 229: 470.CrossRefPubMedGoogle Scholar
  4. Arbisser AI, Donnelly KA, Scott CI Jr, DiFerrante N, Singh J, Stevenson RE, Aylesworth AS, Howell RR (1977) Morquio-like syndrome with beta-galactosidase deficiency and normal hexosamine sulfatase activity: mucopolysaccharidosis IV B. Am. J. Med. Genet. 1: 195-205.CrossRefPubMedGoogle Scholar
  5. Baker HJ Jr, Lindsey JR, McKhann GM, Farrell DF (1971) Neuronal GM1 ganglio-sidosis in a Siamese cat with beta-galactosidase deficiency. Science 174: 838.CrossRefPubMedGoogle Scholar
  6. Bektas M, Spiegel S. (2004) Glycosphingolipids and cell death. Glycoconj J. 20:39-47.CrossRefPubMedGoogle Scholar
  7. Booth CW, GerbieAB, Nadler HL. (1973) Intrauterine diagnosis of GM1 gangliosidosis, type 2. Pediatrics 52: 521-524PubMedGoogle Scholar
  8. Brady RO, Schiffmann R (2004) Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol. 3: 752-756.CrossRefPubMedGoogle Scholar
  9. Caciotti A, Donati MA, Boneh A, d’Azzo A, Federico A, Parini R, Antuzzi D, Bardelli T, Nosi D, Kimonis V, Zammarchi E, Morrone A. (2005) Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis. Hum Mutat. 25: 285-292CrossRefPubMedGoogle Scholar
  10. Chamoles NA, Blanco MB, Iorcansky S, Gaggioli D, Specola N, Casentini C (2001) Retrospective diagnosis of GM1 gangliosidosis by use of a newborn-screening card. Clin Chem. 47:2068.PubMedGoogle Scholar
  11. Colombaioni L, Garcia-Gil M (2004) Sphingolipid metabolites in neural signalling and function. Brain Res Brain Res Rev. 46: 328-355.CrossRefPubMedGoogle Scholar
  12. Derry DM, Fawcett JS, Andermann F, Wolfe LS (1968) Late infantile systemic lipidosis (major monosialogangliosidosis; delineation of two types). Neurology 18: 340-347.PubMedGoogle Scholar
  13. Folkerth RD, Alroy J, Bhan I, Kaye EM (2000) Infantile G(M1) gangliosidosis: Complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination. Pediatr Dev Pathol. 3:73-86.CrossRefPubMedGoogle Scholar
  14. Georgiou T, Drousiotou A, Campos Y, Caciotti A, Sztriha L, Gururaj A, Ozand P, Zammarchi E, Morrone A, D’Azzo A (2004) Four novel mutations in patients from the Middle East with the infantile form of GM1-gangliosidosis. Hum Mutat. 24: 536-537.CrossRefGoogle Scholar
  15. Georgiou T, Stylianidou G, Anastasiadou V, Caciotti A, Campos Y, Zammarchi E, Morrone A, D’azzo A, Drousiotou A (2005) The Arg482His mutation in the beta-galactosidase gene is responsible for a high frequency of GM1 gangliosidosis carriers in a Cypriot village. Genet Test. 9: 126-132.CrossRefPubMedGoogle Scholar
  16. Glaros EN, Kim WS, Quinn CM, Wong J, Gelissen I, Jessup W, Garner B (2005) Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipo-protein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. J Biol Chem. 280: 4515-4523.CrossRefGoogle Scholar
  17. Goldman JE, Katz D, Rapin I, Purpura DP, Suzuki K (1981) Chronic GM1 gangliosidosis presenting as dystonia: I. Clinical and pathological features. Ann Neurol. 9: 465-475.CrossRefPubMedGoogle Scholar
  18. Gururaj A, Sztriha L, Hertecant J, Johansen JG, Georgiou T, Campos Y, Drousiotou A, d’Azzo A (2005) Magnetic resonance imaging findings and novel mutations in GM1 gangliosidosis. J Child Neurol. 20: 57-60.CrossRefPubMedGoogle Scholar
  19. Hanson M, Lupski JR, Hicks J, Metry D (2003) Association of dermal melanocytosis with lysosomal storage disease: Clinical features and hypotheses regarding patho-genesis. Arch. Derm. 139: 916-920.CrossRefPubMedGoogle Scholar
  20. Hinek A, Rabinovitch M (1994) 67-kD elastin-binding protein is a protective “companion” of extracellular insoluble elastin and intracellular tropoelastin. J Cell Biol. 126:563-574.CrossRefPubMedGoogle Scholar
  21. Hinek A, Zhang S, Smith AC, Callahan JW (2000) Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosi-dosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase. Am J Hum Genet. 67:23-36.CrossRefPubMedGoogle Scholar
  22. Itoh M, Matsuda J, Suzuki O, Ogura A, Oshima A, Tai T, Suzuki Y, Takashima S (2001) Development of lysosomal storage in mice with targeted disruption of the beta-galactosidase gene: A model of human GM1-gangliosidosis. Brain Dev. 23(6, Oct): 379-384.CrossRefPubMedGoogle Scholar
  23. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycoproteins, glycopeptides and peptidoglycans (Recommendations 1985). Eur. J. Biochem. 159, 1-6 (1986); Glycoconjugate J. 3,, 123-134 (1986); J Biol Chem. 262, 13-18 (1987); Pure Appl. Chem. 60, 1389-1394 (1988); Royal Society of Chemistry Specialist Periodical Report, Amino acids and peptides, vol. 21, p. 329 (1990).Google Scholar
  24. Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d’Azzo A, Perry VH, Butters TD, Dwek RA, Platt FM (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 126: 974-987.CrossRefPubMedGoogle Scholar
  25. Kasperzyk JL, d’Azzo A, Platt FM, Alroy J, Seyfried TN (2005) Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 ganglio-sidosis mice. J Lipid Res. 46:744-751.CrossRefPubMedGoogle Scholar
  26. Kasperzyk JL, El-Abbadi MM, Hauser EC, D’Azzo A, Platt FM, Seyfried TN (2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem. 89:645-653.CrossRefPubMedGoogle Scholar
  27. Klenk EZ (1942) Gangliosides, a new group of sugar-containing brain lipoids. Physiol Chem 273: 76.Google Scholar
  28. Kreutzer R, Leeb T, Muller G, Moritz A, Baumgartner W (2005) A duplication in the canine {beta}-galactosidase gene GLB1 causes exon skipping and GM1-gangliosi-dosis in Alaskan Huskies. Genetics. 170: 1857-1861.CrossRefPubMedGoogle Scholar
  29. Landing BH, Silverman FN, Craig JM, Jacoby MD, Lahey ME, Chadwick DL (1964) Familial neurovisceral lipidosis. An analysis of eight cases of a syndrome previously reported as Hurler-variant, pseudo-Hurler disease and Tay-Sachs disease with visceral involvement. Am. J. Dis. Child. 108: 503-522.PubMedGoogle Scholar
  30. Lenicker HM, Vassallo Agius P, Young EP, Attard Monsalto SP (1997) Infantile generalized GM1 gangliosidosis: High incidence in the Maltese Islands. J Inherit Metab Dis. 20: 723-724.CrossRefPubMedGoogle Scholar
  31. Lin HC, Tsai FJ, Shen WC, Tsai CH, Peng CT (2000) Infantile form GM1 gangliosidosis with dilated cardiomyopathy: A case report. Acta Paediatr. 89: 880-883.CrossRefPubMedGoogle Scholar
  32. Matsuda J, Suzuki O, Oshima A, Ogura A, Noguchi Y, Yamamoto Y, Asano T, Takimoto K, Sukegawa K, Suzuki Y, Naiki M (1997) Beta-galactosidase-deficient mouse as an animal model for GM1-gangliosidosis. Glycoconj J. 14: 729-736.CrossRefPubMedGoogle Scholar
  33. Matsuda J, Suzuki O, Oshima A, Yamamoto Y, Noguchi A, Takimoto K, Itoh M, Matsuzaki Y, Yasuda Y, Ogawa S, Sakata Y, Nanba E, Higaki K, Ogawa Y, Tominaga L, Ohno K, Iwasaki H, Watanabe H, Brady RO, Suzuki Y (2003) Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc Natl Acad Sci USA. 100: 15912-15917.CrossRefPubMedGoogle Scholar
  34. Mikata, A., Taniguchi, N (1985) Glycosphingolipid. In H. Weigandt (Ed.) Glycolipids. New York: Elsevier, pp. 59-82.Google Scholar
  35. Minelli A, Piantanida M, Simoni G, Rossella F, Romitti L, Brambati B, Danesino C (1992) Prenatal diagnosis of metabolic diseases on chorionic villi obtained before the ninth week of pregnancy. Prenat Diagn. 12: 959-963.CrossRefPubMedGoogle Scholar
  36. Morales A, Colell A, Mari M, Garcia-Ruiz C, Fernandez-Checa JC (2004) Glycosphingo-lipids and mitochondria: Role in apoptosis and disease. Glycoconj J. 20: 579-588.CrossRefPubMedGoogle Scholar
  37. Morreau H, Galjart NJ, Gillemans N, Willemsen R, van der Horst GT, d’Azzo A (1989) Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase-related protein. J Biol Chem. 264: 20655-20663.PubMedGoogle Scholar
  38. Muthane U, Chickabasaviah Y, Kaneski C, Shankar SK, Narayanappa G, Christopher R, Govindappa SS (2004) Clinical features of adult GM1 gangliosidosis: Report of three Indian patients and review of 40 cases. Mov Disord. 19: 1334-1341.CrossRefPubMedGoogle Scholar
  39. Norden AGW, O’Brien, JS (1973) Ganglioside GM1 β-galactosidase: Studies in human liver and brain. Arch Biochem Biophys, 159: 383.CrossRefPubMedGoogle Scholar
  40. O’Brien JS, Storb R, Raff RF, Harding J, Appelbaum F, Morimoto S, Kishimoto Y, Graham T, Ahern-Rindell A, O’Brien SL (1990) Bone marrow transplantation in canine GM1 gangliosidosis. Clin. Genet. 38: 274-280.PubMedCrossRefGoogle Scholar
  41. Okada S, O’Brien JS (1968) Generalized gangliosidosis: Beta-galactosidase deficiency. Science 160: 1002-1004.CrossRefPubMedGoogle Scholar
  42. Oshima A, Tsuji A, Nagao Y, Saturaba H, Suzuki Y (1988) Cloning, sequencing, and expression of cDNA for human beta-galactosidase. Biochem. Biophys. Res. Commun. 157: 238-244.CrossRefPubMedGoogle Scholar
  43. Ozkara HA, Topcu M (2004) Sphingolipidoses in Turkey. Brain Dev. 26(6, Sep): 363-366.CrossRefPubMedGoogle Scholar
  44. Paschke E, Milos I, Kreimer-Erlacher H, Hoefler G, Beck M, Hoeltzenbein M, Kleijer W, Levade T, Michelakakis H, Radeva B (2001) Mutation analyses in 17 patients with deficiency in acid beta-galactosidase: Three novel point mutations and high corre-lation of mutation W273L with Morquio disease type B. Hum Genet. 109: 159-166.CrossRefPubMedGoogle Scholar
  45. Privitera S, Prody CA, Callahan JW, Hinek A (1998) The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein. J. Biol. Chem. 273: 6319-6326.CrossRefPubMedGoogle Scholar
  46. Pshezhetsky AV, Ashmarina M (2001) Lysosomal multienzyme complex: Biochemistry, genetics, and molecular pathophysiology. Prog Nucleic Acid Res Mol Biol. 69: 81-114.CrossRefPubMedGoogle Scholar
  47. Pshezhetsky AV, Potier M (1996) Association of N-acetylgalactosamine-6-sulfate sulfatase with the multienzyme lysosomal complex of beta-galactosidase, cathepsin A, and neuraminidase. Possible implication for intralysosomal catabolism of keratan sulfate. J Biol Chem. 271: 28359-28365.CrossRefPubMedGoogle Scholar
  48. Ramsay SL, Maire I, Bindloss C, Fuller M, Whitfield PD, Piraud M, Hopwood JJ, Meikle PJ (2004) Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: In utero indicators of lysosomal storage diseases. Mol Genet Metab. 83: 231-238.CrossRefPubMedGoogle Scholar
  49. Reynolds GC, Baker HJ, Reynolds RH (1978) Enzyme replacement using liposome carriers in feline GM1 gangliosidosis fibroblasts. Nature 275: 754-755.CrossRefPubMedGoogle Scholar
  50. Ryder SJ, Simmons MM (2001) A lysosomal storage disease of Romney sheep that resembles human type 3 GM1 gangliosidosis. Acta Neuropathol (Berl) 101: 225-228.Google Scholar
  51. Sano R, Tessitore A, Ingrassia A, d’Azzo A (2005) Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood. 106: 2259-2268.CrossRefPubMedGoogle Scholar
  52. Sena-Esteves M, Saeki Y, Fraefel C, Breakefield XO 2000 Correction of acid beta-galactosidase deficiency in GM1 gangliosidosis human fibroblasts by retrovirus vector-mediated gene transfer: Higher efficiency of release and cross-correction by the murine enzyme. Hum Gene Ther. 11: 715-27.CrossRefPubMedGoogle Scholar
  53. Severini MH, Silva CD, Sopelsa A, Coelho JC, Giugliani R (1999) High frequency of type 1 GM1 gangliosidosis in southern Brazil. Clin Genet. 56: 168-169.CrossRefPubMedGoogle Scholar
  54. Shen WC, Tsai FJ, Tsai CH (1998) Myelination arrest demonstrated using magnetic resonance imaging in a child with type I GM1 gangliosidosis. J Formos Med Assoc. 97: 296-269.PubMedGoogle Scholar
  55. Svennerholm L (1970) Comprehensive Biochemistry, vol 18, Amdterdam: Elsevier.Google Scholar
  56. Takano T, Yamanouchi Y (1993) Assignment of human beta-galactosidase-A gene to 3p21.33 by fluorescence in situ hybridization. Hum. Genet. 92: 403-404.CrossRefPubMedGoogle Scholar
  57. Takaura N, Yagi T, Maeda M, Nanba E, Oshima A, Suzuki Y, Yamano T, Tanaka A (2003) Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer. Gene Ther. 10: 1487-1493.CrossRefPubMedGoogle Scholar
  58. Tasso MJ, Martinez-Gutierrez A, Carrascosa C, Vazquez S, Tebar R (1996) GM1-gangliosidosis presenting as nonimmune hydrops fetalis: A case report. J Perinat Med. 24: 445-449.CrossRefPubMedGoogle Scholar
  59. Tessitore A, del P Martin M, Sano R, Ma Y, Mann L, Ingrassia A, Laywell ED, Steindler DA, Hendershot LM, d’Azzo A (2004) GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative ganglio-sidosis. Mol Cell. 15: 753-766.CrossRefPubMedGoogle Scholar
  60. Tifft CJ, Proia RL (2000) Stemming the tide: Glycosphingolipid synthesis inhibitors as therapy for storage diseases. Glycobiology. 10: 1249-1258.CrossRefPubMedGoogle Scholar
  61. Tominaga L, Ogawa Y, Taniguchi M, Ohno K, Matsuda J, Oshima A, Suzuki Y, Nanba E (2001) Galactonojirimycin derivatives restore mutant human beta-galactosidase acti-vities expressed in fibroblasts from enzyme-deficient knockout mouse. Brain Dev. 23:284-287.CrossRefPubMedGoogle Scholar
  62. Tylki-Szymanska A, Maciejko D, Kidawa M, Jablonska-Budaj U, Czartoryska B (1985) Amniotic tissue transplantation as a trial of treatment in some lysosomal storage diseases. J Inherit Metab Dis. 8: 101-104.CrossRefPubMedGoogle Scholar
  63. van der Voorn JP, Kamphorst W, et al. (2004) The leukoencephalopathy of infantile GM1 gangliosidosis: Oligodendrocytic loss and axonal dysfunction. Acta Neuropathol (Berl) 107(6, Jun): 539-545.CrossRefGoogle Scholar
  64. William L., Md. aNyhan, Pinar T., Md. Ozand (1998) Atlas of Metabolic Diseases. 1st ed., Arnold,, p. 534.Google Scholar
  65. Yamato O, Masuoka Y, Yonemura M, Hatakeyama A, Satoh H, Kobayashi A, Nakayama M, Asano T, Shoda T, Yamasaki M, Ochiai K, Umemura T, Maede Y (2003) Clinical and clinico-pathologic characteristics of Shiba dogs with a deficiency of lysosomal acid beta-galactosidase: A canine model of human GM1 gangliosidosis. J Vet Med Sci. 65: 213-217.CrossRefPubMedGoogle Scholar
  66. Yoshida K, Oshima A, Sakuraba H, Nakano T, Yanagisawa N, Inui K, Okada S, Uyama E, Namba R, Kondo K, et al. (1992) GM1 gangliosidosis in adults: Clinical and molecular analysis of 16 Japanese patients. Ann Neurol. 31: 328-332.CrossRefPubMedGoogle Scholar
  67. Yoshida K, Oshima A, Shimmoto M, Fukuhara Y, Sakuraba H, Yanagisawa N, Suzuki Y (1991) Human beta-galactosidase gene mutations in GM1-gangliosidosis: A common mutation among Japanese adult/chronic cases. Am J Hum Genet. 49: 435-442.PubMedGoogle Scholar
  68. Zhang X, Kiechle FL (2004) Review: Glycosphingolipids in health and disease. Ann Clin Lab Sci. 34: 3-13.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Gustavo Charria-Ortiz
    • 1
  1. 1.Department of NeurologyUniversity of Miami School of MedicineMiamiUSA

Personalised recommendations